HSP70 inhibition limits FAK-dependent invasion and enhances the response to melanoma treatment with BRAF inhibitors

Anna Budina-Kolomets, Marie R. Webster, Julia I.Ju Leu, Matthew Jennis, Clemens Krepler, Anastasia Guerrini, Andrew V. Kossenkov, Wei Xu, Giorgos Karakousis, Lynn Schuchter, Ravi K. Amaravadi, Hong Wu, Xiangfan Yin, Qin Liu, Yiling Lu, Gordon Mills, Xiaowei Xu, Donna L. George, Ashani T. Weeraratna, Maureen E. Murphy

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

The stress-inducible chaperone protein HSP70 (HSPA1) is implicated in melanoma development, and HSP70 inhibitors exert tumor-specific cytotoxic activity in cancer. In this study, we documented that a significant proportion of melanoma tumors express high levels of HSP70, particularly at advanced stages, and that phospho-FAK (PTK2) and BRAF are HSP70 client proteins. Treatment of melanoma cells with HSP70 inhibitors decreased levels of phospho-FAK along with impaired migration, invasion, and metastasis in vitro and in vivo. Moreover, the HSP70 inhibitor PET-16 reduced levels of mutant BRAF, synergized with the BRAF inhibitor PLX4032 in vitro, and enhanced the durability of response to BRAF inhibition in vivo. Collectively, these findings provide strong support for HSP70 inhibition as a therapeutic strategy in melanoma, especially as an adjuvant approach for overcoming the resistance to BRAF inhibitors frequently observed in melanoma patients.

Original languageEnglish (US)
Pages (from-to)2720-2730
Number of pages11
JournalCancer Research
Volume76
Issue number9
DOIs
StatePublished - May 1 2016
Externally publishedYes

Fingerprint

Melanoma
Therapeutics
Neoplasms
Proteins
Neoplasm Metastasis
In Vitro Techniques

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Budina-Kolomets, A., Webster, M. R., Leu, J. I. J., Jennis, M., Krepler, C., Guerrini, A., ... Murphy, M. E. (2016). HSP70 inhibition limits FAK-dependent invasion and enhances the response to melanoma treatment with BRAF inhibitors. Cancer Research, 76(9), 2720-2730. https://doi.org/10.1158/0008-5472.CAN-15-2137

HSP70 inhibition limits FAK-dependent invasion and enhances the response to melanoma treatment with BRAF inhibitors. / Budina-Kolomets, Anna; Webster, Marie R.; Leu, Julia I.Ju; Jennis, Matthew; Krepler, Clemens; Guerrini, Anastasia; Kossenkov, Andrew V.; Xu, Wei; Karakousis, Giorgos; Schuchter, Lynn; Amaravadi, Ravi K.; Wu, Hong; Yin, Xiangfan; Liu, Qin; Lu, Yiling; Mills, Gordon; Xu, Xiaowei; George, Donna L.; Weeraratna, Ashani T.; Murphy, Maureen E.

In: Cancer Research, Vol. 76, No. 9, 01.05.2016, p. 2720-2730.

Research output: Contribution to journalArticle

Budina-Kolomets, A, Webster, MR, Leu, JIJ, Jennis, M, Krepler, C, Guerrini, A, Kossenkov, AV, Xu, W, Karakousis, G, Schuchter, L, Amaravadi, RK, Wu, H, Yin, X, Liu, Q, Lu, Y, Mills, G, Xu, X, George, DL, Weeraratna, AT & Murphy, ME 2016, 'HSP70 inhibition limits FAK-dependent invasion and enhances the response to melanoma treatment with BRAF inhibitors', Cancer Research, vol. 76, no. 9, pp. 2720-2730. https://doi.org/10.1158/0008-5472.CAN-15-2137
Budina-Kolomets, Anna ; Webster, Marie R. ; Leu, Julia I.Ju ; Jennis, Matthew ; Krepler, Clemens ; Guerrini, Anastasia ; Kossenkov, Andrew V. ; Xu, Wei ; Karakousis, Giorgos ; Schuchter, Lynn ; Amaravadi, Ravi K. ; Wu, Hong ; Yin, Xiangfan ; Liu, Qin ; Lu, Yiling ; Mills, Gordon ; Xu, Xiaowei ; George, Donna L. ; Weeraratna, Ashani T. ; Murphy, Maureen E. / HSP70 inhibition limits FAK-dependent invasion and enhances the response to melanoma treatment with BRAF inhibitors. In: Cancer Research. 2016 ; Vol. 76, No. 9. pp. 2720-2730.
@article{806e9f92042649128651439e1b2141e9,
title = "HSP70 inhibition limits FAK-dependent invasion and enhances the response to melanoma treatment with BRAF inhibitors",
abstract = "The stress-inducible chaperone protein HSP70 (HSPA1) is implicated in melanoma development, and HSP70 inhibitors exert tumor-specific cytotoxic activity in cancer. In this study, we documented that a significant proportion of melanoma tumors express high levels of HSP70, particularly at advanced stages, and that phospho-FAK (PTK2) and BRAF are HSP70 client proteins. Treatment of melanoma cells with HSP70 inhibitors decreased levels of phospho-FAK along with impaired migration, invasion, and metastasis in vitro and in vivo. Moreover, the HSP70 inhibitor PET-16 reduced levels of mutant BRAF, synergized with the BRAF inhibitor PLX4032 in vitro, and enhanced the durability of response to BRAF inhibition in vivo. Collectively, these findings provide strong support for HSP70 inhibition as a therapeutic strategy in melanoma, especially as an adjuvant approach for overcoming the resistance to BRAF inhibitors frequently observed in melanoma patients.",
author = "Anna Budina-Kolomets and Webster, {Marie R.} and Leu, {Julia I.Ju} and Matthew Jennis and Clemens Krepler and Anastasia Guerrini and Kossenkov, {Andrew V.} and Wei Xu and Giorgos Karakousis and Lynn Schuchter and Amaravadi, {Ravi K.} and Hong Wu and Xiangfan Yin and Qin Liu and Yiling Lu and Gordon Mills and Xiaowei Xu and George, {Donna L.} and Weeraratna, {Ashani T.} and Murphy, {Maureen E.}",
year = "2016",
month = "5",
day = "1",
doi = "10.1158/0008-5472.CAN-15-2137",
language = "English (US)",
volume = "76",
pages = "2720--2730",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - HSP70 inhibition limits FAK-dependent invasion and enhances the response to melanoma treatment with BRAF inhibitors

AU - Budina-Kolomets, Anna

AU - Webster, Marie R.

AU - Leu, Julia I.Ju

AU - Jennis, Matthew

AU - Krepler, Clemens

AU - Guerrini, Anastasia

AU - Kossenkov, Andrew V.

AU - Xu, Wei

AU - Karakousis, Giorgos

AU - Schuchter, Lynn

AU - Amaravadi, Ravi K.

AU - Wu, Hong

AU - Yin, Xiangfan

AU - Liu, Qin

AU - Lu, Yiling

AU - Mills, Gordon

AU - Xu, Xiaowei

AU - George, Donna L.

AU - Weeraratna, Ashani T.

AU - Murphy, Maureen E.

PY - 2016/5/1

Y1 - 2016/5/1

N2 - The stress-inducible chaperone protein HSP70 (HSPA1) is implicated in melanoma development, and HSP70 inhibitors exert tumor-specific cytotoxic activity in cancer. In this study, we documented that a significant proportion of melanoma tumors express high levels of HSP70, particularly at advanced stages, and that phospho-FAK (PTK2) and BRAF are HSP70 client proteins. Treatment of melanoma cells with HSP70 inhibitors decreased levels of phospho-FAK along with impaired migration, invasion, and metastasis in vitro and in vivo. Moreover, the HSP70 inhibitor PET-16 reduced levels of mutant BRAF, synergized with the BRAF inhibitor PLX4032 in vitro, and enhanced the durability of response to BRAF inhibition in vivo. Collectively, these findings provide strong support for HSP70 inhibition as a therapeutic strategy in melanoma, especially as an adjuvant approach for overcoming the resistance to BRAF inhibitors frequently observed in melanoma patients.

AB - The stress-inducible chaperone protein HSP70 (HSPA1) is implicated in melanoma development, and HSP70 inhibitors exert tumor-specific cytotoxic activity in cancer. In this study, we documented that a significant proportion of melanoma tumors express high levels of HSP70, particularly at advanced stages, and that phospho-FAK (PTK2) and BRAF are HSP70 client proteins. Treatment of melanoma cells with HSP70 inhibitors decreased levels of phospho-FAK along with impaired migration, invasion, and metastasis in vitro and in vivo. Moreover, the HSP70 inhibitor PET-16 reduced levels of mutant BRAF, synergized with the BRAF inhibitor PLX4032 in vitro, and enhanced the durability of response to BRAF inhibition in vivo. Collectively, these findings provide strong support for HSP70 inhibition as a therapeutic strategy in melanoma, especially as an adjuvant approach for overcoming the resistance to BRAF inhibitors frequently observed in melanoma patients.

UR - http://www.scopus.com/inward/record.url?scp=84969651143&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969651143&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-15-2137

DO - 10.1158/0008-5472.CAN-15-2137

M3 - Article

C2 - 26984758

AN - SCOPUS:84969651143

VL - 76

SP - 2720

EP - 2730

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 9

ER -